Warnex Will Retain Lab-Services Business as External 'Options' Review Ends | GenomeWeb
NEW YORK (GenomeWeb News) — Warnex last week said it will retain its lab-services business as an external review launched in April to study “various strategic options” for the unit has ended.
 
Warnex's board “has concluded that at the present time, the option which provides the most value for its shareholders is the continued operation of its laboratory-services business,” the company said in a statement.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.